Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $505.75 -2.07%
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of ($12.83), $1.13 worse than the analyst estimate of ($11.70). Revenue for the quarter came in at $2.65 billion versus the consensus estimate of $2.66 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.65-10.85 billion, versus the consensus of $10.762 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
